IN8bio (INAB) to Post Earnings on Thursday

IN8bio (NASDAQ:INAB) is expected to announce its Q2 2026 results before the market opens on Thursday, August 6th. Analysts expect the company to announce earnings of ($0.3437) per share for the quarter. Interested persons may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 4:00 PM ET.

IN8bio (NASDAQ:INAB) last released its earnings results on Thursday, May 7th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.59) by $0.33. On average, analysts expect IN8bio to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

IN8bio Price Performance

Shares of NASDAQ:INAB opened at $1.07 on Thursday. The firm has a market capitalization of $10.54 million, a PE ratio of -0.41 and a beta of 0.22. IN8bio has a 1 year low of $1.05 and a 1 year high of $2.73. The firm’s 50-day moving average is $1.44 and its two-hundred day moving average is $1.64.

Hedge Funds Weigh In On IN8bio

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. HRT Financial LP purchased a new stake in shares of IN8bio during the fourth quarter worth approximately $34,000. Captrust Financial Advisors purchased a new position in IN8bio in the fourth quarter worth approximately $43,000. Citadel Advisors LLC purchased a new position in IN8bio in the third quarter worth approximately $54,000. Two Sigma Investments LP acquired a new position in IN8bio during the 3rd quarter worth approximately $107,000. Finally, Franklin Resources Inc. grew its holdings in IN8bio by 381.6% during the 4th quarter. Franklin Resources Inc. now owns 914,531 shares of the company’s stock worth $2,048,000 after acquiring an additional 724,637 shares in the last quarter. 92.05% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on INAB. HC Wainwright reiterated a “buy” rating on shares of IN8bio in a report on Thursday, June 4th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of IN8bio in a research report on Friday, July 17th. One investment analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IN8bio currently has an average rating of “Hold” and an average price target of $4.00.

IN8bio Company Profile

IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell therapeutic and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are
a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s lead programs consist of INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk
leukemias undergoing haploidentical stem cell transplantation.